Article
|
Open Access
Featured
-
-
Article
| Open AccessA COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.
- Jonas S. Heitmann
- , Tatjana Bilich
- & Juliane S. Walz
-
Letter |
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Neoantigen-targeting vaccines are a feasible therapy for tumours with a low mutation burden and immunologically ‘cold’ tumour microenvironment, as neoantigen-specific T cells from the peripheral blood migrate into intracranial glioblastoma, thereby altering the immune milieu of the glioblastoma.
- Derin B. Keskin
- , Annabelle J. Anandappa
- & David A. Reardon
-
Letter |
An immunogenic personal neoantigen vaccine for patients with melanoma
The results of a phase I trial assessing a personal neoantigen multi-peptide vaccine in patients with melanoma, showing feasibility, safety, and immunogenicity.
- Patrick A. Ott
- , Zhuting Hu
- & Catherine J. Wu